Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 695-702

  Quinn, Suzanne L ^a,b   Lansang, M Cecilia ^a,b   Mina, Deanna ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Insulin resistance; Type 2 diabetes mellitus; U 500 insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIG INSULIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PATIENT REFERRAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WEIGHT CHANGE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79959716367     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.695     Document Type: Article

References (38)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 2010;303:235-41.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes and obesity-related health risk factors. JAMA 2003;289:76-9. (Pubitemid 36026281)
3. Malnick SDH, Knobler H. The medical complications of obesity. Q J Med 2006;99:565-79. (Pubitemid 44540533)
4. Lane WS, Cochran EK, Jackson JA, et al. High dose insulin therapy: is it time for U-500 insulin? Endo Prac 2009;15:71-9.
5. Eli Lilly & Co. Humulin R regular U-500 (concentrated insulin human injection USP rDNA origin) package insert. Indianapolis, IN; 2010.
6. Runy LA. A guide to safer use of dangerous medications: high-alert medications. Hosp Health Netw 2004;78:67-73.
7. Anonymous. 33% of fatal med errors involve insulin therapy. Healthcare Benchmarks Qual Improv 2005;12:31-2.
8. U.S. Food and Drug Administration. Potential signals of serious risks/new safety information identified from the adverse event reporting system (AERS) between January- March 2008. Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm085914.htm. Accessed October 6, 2008.
9. Federico F. Preventing harm from high-alert medications. Jt Comm J Qual Patient Saf 2007;33:537-42.
10. U.S. Department of Veterans Affairs. VA/DoD clinical practice guideline for the management of diabetes mellitus in primary care. Available from http://www.healthquality.va.gov/diabetes/dm-fulltext.pdf. Accessed September 15, 2008.
11. Bastard JP, Maachim M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
12. Phielix E, Szendroedi J, Roden M. Mitochondrial function and insulin resistance during aging - a mini-review [online exclusive article]. Gerontology 2010. Available from http://content.karger.com/ProdukteDB/produkte.asp?doi=10. 1159/000317691.
13. Neal JM. Analysis of effectiveness of human U-500 insulin for patients unresponsive to conventional insulin therapy. Endocr Prac 2005;11:305-7.
14. Ballini P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese markedly insulin-resistant type 2 diabetes. Diabetes Care 2006;29: 2504-5. (Pubitemid 44912260)
15. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes [letter]. Diabetes Care 2006:29:2175-6. (Pubitemid 44871206)
16. Bloom A, Keen H, Watkins PJ. A change to U-100 insulin dosage will reduce error. Br Med J 1981;283:33.
17. Jorgensen KH, Hansen AK, Buschard K. Five-fold increase of insulin concentration delays in the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000;50:161-7.
18. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh) 1969;27(suppl 2):1-84.
19. Eli Lilly & Co. Humalog (insulin lispro injection USP, rDNA origin) package insert. Indianapolis, IN; 2010.
20. Home PD. Insulin therapy. In: Alberti KGMM, Zimmet P, Defronzo RA, eds. International textbook of diabetes, 2nd ed. Chichester, England: John Wiley & Sons Ltd, 1997:189-212.
21. sanofi-aventis U.S. Lantus (insulin glargine, rDNA origin, injection USP) package insert. Bridgewater, NJ; 2010.
22. Novo Nordisk Inc. Levemir (insulin detemir, rDNA origin, injection USP) package insert. Princeton, NJ; 2010.
23. Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab 2008;93:372-4. (Pubitemid 351240804)
24. Porcellati F, Rosetti P, Busciantella NP, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-52. (Pubitemid 47547770)
25. Cochran E, Musso C, Gorden P. The use of U-500 insulin in patients with extreme insulin resistance. Diabetes Care 2005;28:1240-4. (Erratum in Diabetes Care 2007;30:1035.)
26. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year perspective. Medicine (Baltimore) 2004;83:209-22.
27. Arioglu E, Adewelt A, Diabo C, et al. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002;81:87-100.
28. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8. (Pubitemid 34438818)
29. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009;9:37-42.
30. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and insulin resistance in the women's interagency HIV study. J Acquir Defic Syndr 2008;49:369-76.
31. Teplan V, Schuck O, Stollova M, Vitko S. Metabolic syndrome after renal transplantation [in Serbian]. Med Pregl 12007;60(suppl 2):28-32.
32. Petkovska L, Ivanovski N, Dimitrovski C, Serafimoski V. Clinical importance of insulin resistance after renal transplantation in patients on triple immunosuppressive therapy with cyclosporine, corticosteroids and mycofenolate mofetil. Prilozi 2008;29:129-39.
33. Kern PA, Said S, Jackson WG Jr, Michalek JE. Insulin sensitivity following Agent Orange exposure in Vietnam veterans with high blood levels of 2, 3, 7, 8-tetrahydrochlorodibenzo-p-dioxin. J Clin Endocrinol Metab 2004;89:4665-72. (Pubitemid 39244486)
34. Cranmer M, Louie S, Kennedy RH, Kern PA, Fonseca V. Exposure to 2,3,7,8-tetra-cholorodibenzo-p-dioxin (TCDD) is associated with hyperinsulinemia and insulin resistance. Toxicol Sci 2000;56:431-6.
35. Cochran E, Gorden P. Use of U-500 insulin in the treatment of severe insulin resistance. Excerpta Medica 2008;3:211-18.
36. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetes patients. Diabetes Care 2010;33:281-3.
37. Institute for Safe Medication Practices. Medication safety alert: extra caution needed with U-500 insulin. Available from www.ismp/Newsletters/ acutecare/articles/ 19970129.asp. Accessed December 6, 2010.
38. Drugstore.com Online Pharmacy. Insulin. Available from http://www.drugstore.com/pharmacy/drugindex/rxsearch.asp?search=insulin. Accessed December 21, 2010.